- Home
- SST vs KRON Comparison
SST vs KRON Comparison
Compare SST & KRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SST
- KRON
- Stock Information
- Founded
- SST 2013
- KRON 2017
- Country
- SST United States
- KRON United States
- Employees
- SST N/A
- KRON N/A
- Industry
- SST Diversified Commercial Services
- KRON Medicinal Chemicals and Botanical Products
- Sector
- SST Consumer Discretionary
- KRON Health Care
- Exchange
- SST Nasdaq
- KRON Nasdaq
- Market Cap
- SST 73.0M
- KRON 60.3M
- IPO Year
- SST N/A
- KRON 2020
- Fundamental
- Price
- SST $0.97
- KRON $0.85
- Analyst Decision
- SST Hold
- KRON Buy
- Analyst Count
- SST 1
- KRON 3
- Target Price
- SST $2.00
- KRON $1.63
- AVG Volume (30 Days)
- SST 110.9K
- KRON 121.3K
- Earning Date
- SST 11-07-2024
- KRON 11-13-2024
- Dividend Yield
- SST N/A
- KRON N/A
- EPS Growth
- SST N/A
- KRON N/A
- EPS
- SST N/A
- KRON N/A
- Revenue
- SST $364,450,000.00
- KRON $9,865,000.00
- Revenue This Year
- SST N/A
- KRON $52.58
- Revenue Next Year
- SST $15.17
- KRON N/A
- P/E Ratio
- SST N/A
- KRON N/A
- Revenue Growth
- SST N/A
- KRON 146.56
- 52 Week Low
- SST $0.91
- KRON $0.69
- 52 Week High
- SST $3.02
- KRON $1.60
- Technical
- Relative Strength Index (RSI)
- SST 40.08
- KRON 40.22
- Support Level
- SST $1.03
- KRON $0.83
- Resistance Level
- SST $1.17
- KRON $0.98
- Average True Range (ATR)
- SST 0.08
- KRON 0.06
- MACD
- SST 0.00
- KRON -0.01
- Stochastic Oscillator
- SST 19.96
- KRON 25.00
About SST System1 Inc.
System1 Inc develops technology and data science to operate a responsive acquisition marketing platform. It serves customers in the areas of health and wellness, automotive, finance, travel, and entertainment. The company's segment includes Owned and Operated Advertising (O&O); and Partner Network. It generates maximum revenue from the Owned and Operated Advertising (O&O) segment.
About KRON Kronos Bio Inc.
Kronos Bio Inc is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics designed to transform patient outcomes through a precision medicine plan by targeting dysregulated transcription. The company operates in one business segment, the development of biopharmaceutical products.